FDA Supports FluMist Use, Releases Lots For 2016 Flu Season
Despite a CDC advisory committee recommendation that FluMist not be used in the forthcoming influenza season, FDA says the benefits of the nasal formulation outweigh any potential risks.
You may also be interested in...
US FDA's approval kept very limited amounts available the past two flu seasons; 2.7 million doses to be shipped for the 2018-2019 season.
CDC advisory committee wants vaccine effectiveness data for H1N1 component but that is not the predominant strain this season; AstraZeneca is not giving up.
After a CDC advisory committee recommends against the nasal flu vaccine's use in any setting, sponsor AstraZeneca looks to reconcile its effectiveness results with government findings.